Company research
EXACT SCIENCES CORP
CIK 1124140Updated Sep 24, 2026
Securities
Historical securities (1)
EXAS · NASDAQ · equity · closed Mar 20, 2026Name history
EXACT CORP · through Jan 8, 2001
EXAS price & chart
Historical security
This listing closed Mar 20, 2026. Live provider charts are shown only for current listings.
About the company
Exact Sciences’ Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score® test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX test is recognized as the standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra® test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today. Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine, by applying real-world evidence and guideline recommendations. To learn more, visit precisiononcology.exactsciences.com.
In the news
Halper Sadeh LLC Encourages FRGE, EXAS, CIVI, KVUE Shareholders to Contact the Firm to Discuss Their Rights News provided by Halper Sadeh LLP Jan 08, 2026, 12:48 ET Share this article Share to X Share this article Share to X Shareholders should contact the firm as there may be limited time to enforc ↗
Recent filings
15-12G filing
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
POSASR filing
S-8 POS filing
S-8 POS filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 5,860,629,000Source | 5,928,139,000Source | 6,471,334,000Source | 6,226,873,000Source |
| Property, Plant and Equipment, NetUSD | 708,664,000Source | 693,673,000Source | 698,354,000Source | 684,756,000Source |
| GoodwillUSD | 2,368,048,000Source | 2,366,676,000Source | 2,367,120,000Source | 2,346,040,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 919,925,000Source | 1,009,693,000Source | 1,890,396,000Source | 1,956,240,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 955,996,000Source | 600,889,000Source | 605,378,000Source | 242,493,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 298,653,000Source | 248,968,000Source | 203,623,000Source | 158,043,000Source |
| Inventory, NetUSD | 166,201,000Source | 162,383,000Source | 127,475,000Source | 118,259,000Source |
| Assets, CurrentUSD | 1,555,849,000Source | 1,571,423,000Source | 1,194,369,000Source | 982,257,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 126,284,000Source | 122,046,000Source | 85,627,000Source | 73,898,000Source |
| Operating Lease, Right-of-Use AssetUSD | 122,332,000Source | 116,952,000Source | 143,708,000Source | 167,003,000Source |
| Other Assets, NoncurrentUSD | 185,811,000Source | 169,722,000Source | 177,387,000Source | 90,577,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,459,577,000Source | 3,525,890,000Source | 3,326,029,000Source | 3,183,711,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,909,000Source | 1,857,000Source | 1,815,000Source | 1,780,000Source |
| Retained Earnings (Accumulated Deficit)USD | -4,705,981,000Source | -4,498,032,000Source | -3,469,175,000Source | -3,265,026,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,358,000Source | -944,000Source | 1,428,000Source | -5,236,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,401,052,000Source | 2,402,249,000Source | 3,145,305,000Source | 3,043,162,000Source |
| Additional Paid in Capital, Common StockUSD | 7,102,766,000Source | 6,899,368,000Source | 6,611,237,000Source | 6,311,644,000Source |
| Liabilities and EquityUSD | 5,860,629,000Source | 5,928,139,000Source | 6,471,334,000Source | 6,226,873,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 641,152,000Source | 732,187,000Source | 514,701,000Source | 412,747,000Source |
| Operating Lease, Liability, CurrentUSD | 33,591,000Source | 27,405,000Source | 29,379,000Source | 28,366,000Source |
| Accounts Payable, CurrentUSD | 175,868,000Source | 89,572,000Source | 78,816,000Source | 74,916,000Source |
| Operating Lease, Liability, NoncurrentUSD | 161,931,000Source | 157,133,000Source | 161,070,000Source | 182,399,000Source |
| Other Liabilities, NoncurrentUSD | 329,317,000Source | 315,503,000Source | 335,982,000Source | 352,459,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 416,473,000Source | 328,292,000Source | 341,683,000Source | 299,216,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 964,711,000Source | 1,038,026,000Source | 777,644,000Source | 632,057,000Source |
| Deferred Tax Liabilities, NetUSD | 5,806,000Source | 7,170,000Source | 17,289,000Source | 19,713,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -207,949,000Source | -1,028,857,000Source | -204,149,000Source | -623,506,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 217,666,000Source | 214,885,000Source | 231,312,000Source | 206,823,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 48,891,000Source | 46,259,000Source | 43,416,000Source | -61,088,000Source |
| Increase (Decrease) in InventoriesUSD | 3,772,000Source | 34,911,000Source | 7,690,000Source | 13,231,000Source |
| Increase (Decrease) in Accounts PayableUSD | 214,042,000Source | 43,538,000Source | 82,750,000Source | -52,180,000Source |
| Deferred Income Tax Expense (Benefit)USD | -1,544,000Source | -10,119,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 491,438,000Source | 210,536,000Source | 156,119,000Source | -223,559,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | 0Source | 52,413,000Source | 14,686,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 195,121,000Source | -442,155,000Source | 49,679,000Source | 74,066,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | -297,000Source | 225,000Source | -250,000Source | 549,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 134,656,000Source | 135,989,000Source | 124,190,000Source | 214,462,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 86,477,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -338,090,000Source | 231,874,000Source | 159,766,000Source | 76,485,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -11,887,000Source | -17,754,000Source | -9,751,000Source | -5,530,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 349,360,000Source | -3,039,000Source | 366,885,000Source | -72,978,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 955,996,000Source | 606,636,000Source | 609,675,000Source | 242,790,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 30,444,000Source | 27,839,000Source | 18,776,000Source | 11,519,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 891,000Source | -3,294,000Source | 1,321,000Source | 30,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 217,666,000Source | 214,885,000Source | 231,312,000Source | 206,823,000Source |
| Amortization of Debt Issuance CostsUSD | 4,609,000Source | 5,296,000Source | 5,350,000Source | 5,727,000Source |
| Amortization of Intangible AssetsUSD | 96,700,000Source | 95,158,000Source | 92,160,000Source | 97,450,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 964,711,000Source | 1,038,026,000Source | 777,644,000Source | 632,057,000Source |
| Debt and Equity Securities, Realized Gain (Loss)USD | — | 0Source | — | — |
| DepreciationUSD | 124,879,000Source | 119,701,000Source | — | — |
| Equity Securities, FV-NI, Gain (Loss)USD | 3,081,000Source | -2,713,000Source | 4,098,000Source | -21,774,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | 0Source | 0Source | -13,244,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | 10,254,000Source | 10,324,000Source | 0Source |
| General and Administrative ExpenseUSD | 888,674,000Source | 781,825,000Source | 893,204,000Source | 737,304,000Source |
| GoodwillUSD | 2,368,048,000Source | 2,366,676,000Source | 2,367,120,000Source | 2,346,040,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | — | — | — |
| Income Tax Expense (Benefit)USD | 4,061,000Source | -7,304,000Source | 2,403,000Source | -9,064,000Source |
| InterestExpenseNonoperatingUSD | 39,361,000Source | 27,016,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -207,949,000Source | -1,028,857,000Source | -204,149,000Source | -623,506,000Source |
| Nonoperating Income (Expense)USD | 2,410,000Source | 12,542,000Source | 13,266,000Source | -39,059,000Source |
| Operating ExpensesUSD | 2,469,053,000Source | 2,976,620,000Source | — | — |
| Operating Lease, ExpenseUSD | 27,040,000Source | 26,926,000Source | 27,891,000Source | 28,639,000Source |
| Other Operating Income (Expense), NetUSD | 0Source | 9,200,000Source | 78,427,000Source | -13,244,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 3,200,000Source | 6,500,000Source |
| Restructuring CostsUSD | 22,169,000Source | — | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 3,246,990,000Source | 2,758,867,000Source | 2,499,766,000Source | 2,084,279,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 3,246,990,000Source | 2,758,867,000Source | 2,499,766,000Source | 2,084,279,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -206,298,000Source | -1,048,703,000Source | -215,012,000Source | -593,511,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -203,888,000Source | -1,036,161,000Source | -201,746,000Source | -632,570,000Source |
| Income Tax Expense (Benefit)USD | 4,061,000Source | -7,304,000Source | 2,403,000Source | -9,064,000Source |
| Net Income (Loss) Attributable to ParentUSD | -207,949,000Source | -1,028,857,000Source | -204,149,000Source | -623,506,000Source |
| Earnings Per Share, BasicUSD per share | -1.1Source | -5.59Source | -1.13Source | -3.54Source |
| Earnings Per Share, DilutedUSD per share | -1.1Source | -5.59Source | -1.13Source | -3.54Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 188,688,000Source | 184,197,000Source | 180,144,000Source | 176,351,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 188,688,000Source | 184,197,000Source | 180,144,000Source | 176,351,000Source |
| Interest Expense (non-operating)USD | 39,361,000Source | 27,016,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 96,700,000Source | 95,158,000Source | 92,160,000Source | 97,450,000Source |
| Costs and ExpensesUSD | — | — | 2,793,205,000Source | 2,664,546,000Source |
| Debt and Equity Securities, Realized Gain (Loss)USD | — | 0Source | — | — |
| General and Administrative ExpenseUSD | 888,674,000Source | 781,825,000Source | 893,204,000Source | 737,304,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 2,262,755,000Source | 1,918,717,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -220,010,000Source | -1,036,306,000Source | -204,128,000Source | -617,240,000Source |
| Interest ExpenseUSD | — | — | 19,447,000Source | 19,634,000Source |
| Interest Expense, DebtUSD | 32,866,000Source | 22,314,000Source | 13,204,000Source | 16,140,000Source |
| Nonoperating Income (Expense)USD | 2,410,000Source | 12,542,000Source | 13,266,000Source | -39,059,000Source |
| Operating ExpensesUSD | 2,469,053,000Source | 2,976,620,000Source | — | — |
| Operating Lease, ExpenseUSD | 27,040,000Source | 26,926,000Source | 27,891,000Source | 28,639,000Source |
| Other Operating Income (Expense), NetUSD | 0Source | 9,200,000Source | 78,427,000Source | -13,244,000Source |
| Reclassification from AOCI, Current Period, before Tax, Attributable to ParentUSD | 976,000Source | -49,000Source | -3,927,000Source | -226,000Source |
| Research and Development ExpenseUSD | 522,996,000Source | 431,210,000Source | 425,882,000Source | 393,418,000Source |
| Restructuring and Related Cost, Incurred CostUSD | 73,213,000Source | — | — | — |
| Restructuring CostsUSD | 22,169,000Source | — | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 3,246,990,000Source | 2,758,867,000Source | 2,499,766,000Source | 2,084,279,000Source |
| Selling and Marketing ExpenseUSD | 1,050,183,000Source | 894,125,000Source | 727,090,000Source | 846,011,000Source |
Filing attachments
d128802dex41.htm · 8-K · 2026-03-23
EX-4.1 4 d128802dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SIXTH SUPPLEMENTAL INDENTURE THIS SIXTH SUPPLEMENTAL INDENTURE (this “Sixth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as …
Read attachment ↗d128802dex42.htm · 8-K · 2026-03-23
EX-4.2 5 d128802dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 SEVENTH SUPPLEMENTAL INDENTURE THIS SEVENTH SUPPLEMENTAL INDENTURE (this “Seventh Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dat…
Read attachment ↗d128802dex43.htm · 8-K · 2026-03-23
EX-4.3 6 d128802dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 EIGHTH SUPPLEMENTAL INDENTURE THIS EIGHTH SUPPLEMENTAL INDENTURE (this “Eighth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), an…
Read attachment ↗d128802dex44.htm · 8-K · 2026-03-23
EX-4.4 7 d128802dex44.htm EX-4.4 EX-4.4 Exhibit 4.4 NINTH SUPPLEMENTAL INDENTURE THIS NINTH SUPPLEMENTAL INDENTURE (this “Ninth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), and t…
Read attachment ↗exas-20260213xex991.htm · 8-K · 2026-02-13
EX-99.1 2 exas-20260213xex991.htm EX-99.1 Document EXHIBIT 99.1 Investor Contact: Derek Leckow Exact Sciences Corp. investorrelations@exactsciences.com 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. sspanos@exactsciences.com 608-556-4380 For Immediate Release Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results Fourth quarter and 2025 highlights • Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue…
Read attachment ↗d38144dex991.htm · 8-K · 2025-11-20
EX-99.1 3 d38144dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Press Release Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments Acquisition adds a new growth vertical to Abbott’s already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments Acquisition will uniquely position Abbott to transform cancer care, advan…
Read attachment ↗